Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer

Summary

Active vaccination with tumor specific antigens and VEGFR1 HLA-A24 epitopes can improve survival of patients with advanced Gastric Cancer.

Timeline

Start

2010-11

Primary completion

2016-11

Completion

2017-06

Outcome

Met primary endpoint

release “がんペプチドワクチンカクテル「OTSGC-A24」の胃がんに対する第 I/II相臨床試験が終了し、主たる目的であった安全性及び免疫誘導につきまして良好な結果が確認されました” oncotherapy.co.jp ↗

Publications

• Background Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005;10 Suppl 3:49-58. doi: 10.1634/theoncologist.10-90003-49.
• Background Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006 Jun 20;24(18):2903-9. doi: 10.1200/JCO.2005.05.0245.
• Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer. 2018 Mar 27;18(1):332. doi: 10.1186/s12885-018-4234-8.

Drugs

Indications